ABBVNYSEChecked

What is AbbVie tied to?

AbbVie makes medicines for immune diseases, brain and nerve conditions and cancer, plus Botox. Its two immune drugs, Skyrizi and Rinvoq, brought in $8.48 billion of its $17.40 billion of revenue in the third quarter of 2026, as sales of its older drug Humira kept falling.

Biggest ties: Johnson & Johnson (Imbruvica partner); Genentech (Roche) (Venclexta partner); Drug wholesalers (McKesson, Cardinal Health, Cencora)

The map

Suppliers sit above AbbVie, customers below. Tap a box, or step through with the arrows.

AbbVie depends on1 of 8

Johnson & Johnson

Size$522 million of Imbruvica sales (Q3 2026)

AbbVie and J&J's Janssen unit develop and sell the cancer drug Imbruvica together and share the profits. In the US, Janssen's share was $158 million in the third quarter of 2026; outside the US, J&J sells it and AbbVie's share was $182 million.

What to watch: Imbruvica sales, down 26% to $522 million.

Open Johnson & Johnson's map

Boxes with a corner arrow have their own map. Sizes show where a source gives one.

Outside forces

Things AbbVie can't control that affect its business. Tap one to see what to watch.

Two drugs carry growthSkyrizi and Rinvoq together made up about 42% of AbbVie's revenue in 2025, each over 10%.What to watch

Any new rival in psoriasis or bowel disease.

Source: PolicyRisk: AbbVie 10-K disclosuresChecked

Humira copiesHumira has lost its exclusive US rights, letting copies in. Its sales fell 31% to $683 million in the third quarter of 2026.What to watch

How much further Humira falls.

Sources: Biopharma Watch: AbbVie Q3 2026 release; AbbVie: full year and fourth quarter 2025 resultsChecked

Buying new drugsCharges for buying drugs in development cut 2026 adjusted earnings by $0.69 a share through the third quarter.What to watch

More deals, which AbbVie does not include in its forecasts.

Source: Earnings Whispers: AbbVie Q3 2026 releaseChecked

Latest earnings

Q3 2026, quarter to Sep 30, 2026

Reported Oct 30, 2026Next report date not announced yet

Revenue

$17.40B

Up 10% from $15.78B a year earlier

Earnings per share

$2.37

Up 2270% from $0.10 a year earlier

The year-earlier figure was unusually low. Adjusted earnings per share, which leave out some one-time items, rose to $3.82 from $1.86.

Sales, last four quartersIn billions of dollars. The last bar is the quarter above.
  1. $16.62BOct–Dec
    2025
  2. $15.00BJan–Mar
    2026
  3. $16.99BApr–Jun
    2026
  4. $17.40BJul–Sep
    2026

Source: Stock Analysis: ABBV quarterly income statementChecked

Company outlook: AbbVie expects 2026 revenue of about $67.8 billion and fourth-quarter revenue of about $18.4 billion.

Ties to the map: Immune drugs sold through the wholesalers on the map grew 16%, while Imbruvica, shared with J&J, fell 26%.

Compared with the same quarter a year earlier, as reported by the company.

Sources: AbbVie: third-quarter 2026 results (SEC); What AbbVie said on its Q3 2026 call

Where the money comes from

Share of AbbVie's sales by business and region. Third quarter of 2026, as reported by the company.

By business

  • Immunology53%$9.17B
  • Neuroscience19%$3.39B
  • Oncology10%$1.70B
  • Aesthetics7%$1.18B
  • Other11%$1.97B

By region

  • United States77%$13.33B
  • Outside the US23%$4.07B

Other includes Mavyret, Creon and Linzess, $0.97 billion together, and smaller medicines.

Source: AbbVie: third-quarter 2026 results (SEC)Checked

Competes with

More in Drugmakers

Common questions

What are AbbVie's biggest drugs?

Skyrizi, with $5.78 billion of sales in the third quarter of 2026, and Rinvoq, with $2.71 billion. Together they were about 42% of revenue in 2025.

Does AbbVie still sell Humira?

Yes, but sales fell 31% to $683 million in the third quarter of 2026 after it lost its exclusive US rights.

Who did AbbVie buy in 2026?

Apogee Therapeutics, for about $10.9 billion in cash, completed in September 2026. It adds an eczema drug in late-stage testing.

Read every connection

All 8 connections as cards, with sources. It's the same detail you get by tapping a box on the map.
Show allHide

Suppliers

The companies AbbVie relies on to make what it sells, with sources.

Johnson & Johnson

Imbruvica partner

Size$522 million of Imbruvica sales (Q3 2026)

AbbVie and J&J's Janssen unit develop and sell the cancer drug Imbruvica together and share the profits. In the US, Janssen's share was $158 million in the third quarter of 2026; outside the US, J&J sells it and AbbVie's share was $182 million.

What to watch: Imbruvica sales, down 26% to $522 million.

Sources: AbbVie 10-Q for the third quarter of 2026 (SEC); AbbVie 10-K for 2025 (SEC); AbbVie: third-quarter 2026 results (SEC)Checked

Genentech (Roche)

Venclexta partner

Size$284 million to Genentech (Q1 2026)

AbbVie and Genentech, part of Roche, develop and sell the cancer drug Venclexta together. Genentech's share of profits and royalties was $284 million in the first quarter of 2026.

What to watch: How the profit split changes as Venclexta grows.

Source: AbbVie 10-Q for the first quarter of 2026 (SEC)Checked

Genmab

Epkinly partner

Size$108 million (Q3 2026)

Epkinly, a cancer drug, is developed by AbbVie and Genmab together. Its sales rose 58% to $108 million in the third quarter of 2026, with US profits shared.

What to watch: Whether Epkinly becomes a large seller.

Source: AbbVie: third-quarter 2026 results (SEC)Checked

RemeGen

Cancer drug license

Size not disclosed in our sources

In March 2026 AbbVie completed a license deal with RemeGen for a two-target antibody being tested against several solid tumors.

What to watch: Trial progress of the licensed drug.

Source: AbbVie 10-Q for the first quarter of 2026 (SEC)Checked

Customers

Who buys from AbbVie or pays it, with sources.

Drug wholesalers

McKesson, Cardinal Health, Cencora

SizeUp to 43% of US gross revenue from one

Three wholesalers, McKesson, Cardinal Health and Cencora, handled substantially all of AbbVie's US drug sales in 2025, with one taking up to 43% of US gross revenue. The US was $13.33 billion of third-quarter 2026 revenue.

What to watch: How much of US sales runs through each wholesaler.

Sources: PolicyRisk: AbbVie 10-K disclosures; AbbVie: third-quarter 2026 results (SEC)Checked

About this page

Connections were last checked against company filings and news reports on Nov 21, 2026. Companies don't have to disclose every supplier or customer, so this map shows the most important ones that are publicly known, not every link.

How we check connections. StockTies is for information only. It is not investment advice. Spot something out of date? Tell us.